David Lewis

Morgan Stanley Upgrades Medtronic On Exposure To COVID-19 Recovery

COVID-19 Testing Stocks Move Lower After Abbott Receives EUA For 15-Minute Test

Morgan Stanley Says Edwards Lifesciences Settlement With Abbott An 'Expensive Positive'

COVID-19 Testing Stocks Move Lower After Abbott Receives EUA For 15-Minute Test

Morgan Stanley Says Edwards Lifesciences Settlement With Abbott An 'Expensive Positive'

Analysts Constructive On Intuitive Surgical Following Solid Quarter

Analysts, Investors Like Johnson & Johnson's Improvement, But Lawsuits Loom

Analysts Constructive On Intuitive Surgical Following Solid Quarter

Analysts, Investors Like Johnson & Johnson's Improvement, But Lawsuits Loom

Sell-Side Positive On Johnson & Johnson's Unexpected Ohio Opioid Settlement

Why One Johnson & Johnson Analyst Sees Oklahoma Opioid Ruling As Near-Term Sentiment Positive

David Lewis Recent News

Intuitive Surgical's Q2 Performance Lauded By Bullish Analysts

After Earnings Beat, Wall Street Talks Johnson & Johnson Litigation Risk

Morgan Stanley: Medtronic's $4B Financing Could Be 10-Cent EPS Tailwind

Johnson & Johnson Analysts Laud Accelerating Pharma Business

Analysts View Johnson & Johnson's Organic Growth Guidance As Conservative

Analysts Unfazed By Intuitive Surgical's Higher Opex Guidance

Analysts Stand By Johnson & Johnson Despite Earnings Pullback

Morgan Stanley Finds A Few Reasons To Double Upgrade Baxter

Morgan Stanley Downgrades Hologic On Tough Cynosure Recovery, Surgery Business Risks

Johnson & Johnson's Asbestos Woes: Experts Speak Up

3 Reasons Why Nevro Corp. Was Downgraded By Morgan Stanley

Analyst: Intuitive Surgical Is Moving Into Its 'Most Catalyst Rich' Cycle Ever

Abbott Labs Has 'An Emerging Picture Of Top-Tier Growth,' Says Morgan Stanley

Morgan Stanley Turns Bullish On Haemonetics

On The Detroit River, America's Only Floating Post Office Blends Tradition And Technology

Intuitive Surgical's Sp Ushers In The Next Phase Of Growth Story

Here's Every Sell-Side Rating Following iRhythm's IPO Quiet Period Expiration

Hill-Rom Story Not Appreciated By Wall Street, Says Morgan Stanley

Nevro Has A Multi-Billion Dollar Opportunity

Johnson & Johnson Sales Fall: What The Street Is Saying Now

Everyone's Talking About ROLARR Heading Into Intuitive Surgical Earnings: Here's What It Means

Johnson & Johnson Faces Pressure From U.S. Patent Office

UPDATE: Morgan Stanley Initiates Coverage On Intuitive Surgical